Abraxane for Injectable Suspension
GPTKB entity
Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemotherapy drug
|
| gptkbp:activeDuring |
paclitaxel
|
| gptkbp:chemicalFormula |
C47H51NO14
|
| gptkbp:clinicalTrials |
oncology
Phase III ABRAXANE trial MPC-350-001_trial MPC-350-002_trial MPC-350-003_trial MPC-350-004_trial |
| gptkbp:contraindication |
anemia
allergic reactions vomiting diarrhea constipation infection thrombocytopenia severe liver impairment hypersensitivity to paclitaxel stomatitis |
| gptkbp:date |
FDA_approved
|
| gptkbp:distribution |
approximately 1000 L
|
| gptkbp:dosageForm |
suspension
|
| gptkbp:drugInterdiction |
antineoplastic agent
protein-bound |
| gptkbp:firstAppearance |
2005
|
| gptkbp:formulation |
injectable suspension
|
| gptkbp:hasVariants |
with carboplatin
with gemcitabine |
| https://www.w3.org/2000/01/rdf-schema#label |
Abraxane for Injectable Suspension
|
| gptkbp:isATypeOf |
97058-78-3
|
| gptkbp:mandates |
metastatic breast cancer
metastatic non-small cell lung cancer metastatic pancreatic cancer |
| gptkbp:manufacturer |
gptkb:Celgene_Corporation
|
| gptkbp:numberOfStudents |
13 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
L01CD01
|
| gptkbp:packaging |
vial
|
| gptkbp:route |
intravenous
IV infusion |
| gptkbp:sells |
gptkb:Abraxane
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
fatigue
nausea peripheral neuropathy hair loss neutropenia |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
microtubule inhibitor
|
| gptkbp:usedFor |
treatment of pancreatic cancer
treatment of breast cancer treatment of non-small cell lung cancer |
| gptkbp:waterManagement |
bile
|